A Prospective Cohort Study of COVID-19 : Evaluation of the Early Role of IL-1 and IL-6 Antagonists in Improving the Outcome of the Illness and Reduction in the Risk of Death
The COVID-19 pandemic had a profound impact on global health, economies, and social systems. The crucial factor that determines the success of COVID-19 treatments is preventing the need for mechanical ventilation and intensive care admission. In the context of COVID-19, several treatments have been found to play a role in the disease's progression and severity. Interleukins (ILs) have been identified as key mediators of the cytokine storm that can occur in severe cases of COVID-19, leading to respiratory failure and other complications. For instance, IL-1 antagonist (anakinra) and IL-6 antagonist (tocilizumab) are supposed to be promising treatments as well as cortisones for COVID-19. This prospective study aims to evaluate the effectiveness of anakinra or tocilizumab in addition to cortisone in preventing the progression of mild to moderate COVID-19 cases to severe intensive care admission. Biochemical and hematological parameters, such as D-dimer, ferritin, LDH, CRP, and white blood cells (WBCs), were measured after treatment with either anakinra or tocilizumab in addition to cortisone or cortisone alone. The study also recorded the number of deaths and patients admitted to intensive care. The results indicate that anakinra significantly improved outcomes and decreased the number of intensive care admissions compared to tocilizumab or cortisone alone. Therefore, anakinra may play a vital role in controlling the progression of COVID-19, and its use in mild to moderate cases may prevent the worsening of the disease to severe stages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Healthcare (Basel, Switzerland) - 11(2023), 7 vom: 03. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Kharusi, Mardheya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anakinra |
|---|
| Anmerkungen: |
Date Revised 15.04.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/healthcare11071025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355513110 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355513110 | ||
| 003 | DE-627 | ||
| 005 | 20231226064511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/healthcare11071025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355513110 | ||
| 035 | |a (NLM)37046952 | ||
| 035 | |a (PII)1025 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Kharusi, Mardheya |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Prospective Cohort Study of COVID-19 |b Evaluation of the Early Role of IL-1 and IL-6 Antagonists in Improving the Outcome of the Illness and Reduction in the Risk of Death |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The COVID-19 pandemic had a profound impact on global health, economies, and social systems. The crucial factor that determines the success of COVID-19 treatments is preventing the need for mechanical ventilation and intensive care admission. In the context of COVID-19, several treatments have been found to play a role in the disease's progression and severity. Interleukins (ILs) have been identified as key mediators of the cytokine storm that can occur in severe cases of COVID-19, leading to respiratory failure and other complications. For instance, IL-1 antagonist (anakinra) and IL-6 antagonist (tocilizumab) are supposed to be promising treatments as well as cortisones for COVID-19. This prospective study aims to evaluate the effectiveness of anakinra or tocilizumab in addition to cortisone in preventing the progression of mild to moderate COVID-19 cases to severe intensive care admission. Biochemical and hematological parameters, such as D-dimer, ferritin, LDH, CRP, and white blood cells (WBCs), were measured after treatment with either anakinra or tocilizumab in addition to cortisone or cortisone alone. The study also recorded the number of deaths and patients admitted to intensive care. The results indicate that anakinra significantly improved outcomes and decreased the number of intensive care admissions compared to tocilizumab or cortisone alone. Therefore, anakinra may play a vital role in controlling the progression of COVID-19, and its use in mild to moderate cases may prevent the worsening of the disease to severe stages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 treatment | |
| 650 | 4 | |a IL-1 antagonist | |
| 650 | 4 | |a IL-6 antagonist | |
| 650 | 4 | |a Interleukins | |
| 650 | 4 | |a anakinra | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Al Sheikh, Naffesa |e verfasserin |4 aut | |
| 700 | 1 | |a Alhajri, Maiya |e verfasserin |4 aut | |
| 700 | 1 | |a Al Mandhri, Seif Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Khafagy, El-Sayed |e verfasserin |4 aut | |
| 700 | 1 | |a Moglad, Ehssan H |e verfasserin |4 aut | |
| 700 | 1 | |a Alotaibi, Hadil Faris |e verfasserin |4 aut | |
| 700 | 1 | |a Hegazy, Wael A H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Healthcare (Basel, Switzerland) |d 2013 |g 11(2023), 7 vom: 03. Apr. |w (DE-627)NLM253742684 |x 2227-9032 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:7 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/healthcare11071025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 7 |b 03 |c 04 | ||